Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel ...

Wetteny Joseph, CFO of Zoetis, says tariffs are manageable and animal health remains resilient. He supports tax policies that ...

I remain positive on Phibro's long-term prospects and would look to buy on dips, as structural improvements appear ...

Zoetis was created in 2013 after splitting off from Pfizer’s animal health division. While it may not seem like a household ...

Infosys has announced a strategic partnership with Zoetis to enhance the latter's IT operations using AI and automation. This ...

Zoetis published its 2024 Sustainability Progress Update "Advancing Sustainability in Animal Health for a Better Future" to ...

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal ...

Zoetis Inc. closed 19.30% below its 52-week high of $200.33, which the company achieved on September 19th.

Infosys partners with Zoetis to enhance digital capabilities in animal health industry, focusing on AI solutions and automation services.

Infosys is expected to improve Zoetis’ operational efficiency and help the former with its long-term business objectives.

Zoetis Inc. closed 17.97% short of its 52-week high of $200.33, which the company reached on September 19th.

Editor’s note: This interview has been edited for length and clarity.